Šalis: Australija
kalba: anglų
Šaltinis: Department of Health (Therapeutic Goods Administration)
Insulin detemir
Novo Nordisk Pharmaceuticals Pty Ltd
Medicine Registered
Product Information page 1 Levemir (TZD warning etc SRN) dpi1a.doc PRODUCT INFORMATION LEVEMIR ® PENFILL ® LEVEMIR ® FLEXPEN ® NAME OF THE DRUG Insulin detemir Insulin detemir (rys) has the empirical formula C 267 H 402 N 64 O 76 S 6 and a molecular weight of 5916.9 . (A1) (A21) (B1) (B29) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn Cys Leu His Gln Asn Val Phe Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys NH C O S S S S S S CAS no. 169148-63-4 DESCRIPTION Levemir ® is a soluble, basal insulin analogue with a prolonged duration of effect. Insulin detemir (rys) is produced by recombinant DNA technology using _Saccharomyces cerevisiae_. One unit of insulin detemir contains 0.142 mg salt-free anhydrous insulin detemir. One unit (U) of insulin detemir corresponds nominally to one IU (international unit) of human insulin. Levemir is a clear, colourless, neutral solution of insulin detemir 100 U/mL. Levemir is a solution for injection. Levemir also contains the following inactive ingredients: glycerol, phenol, meta-cresol, zinc acetate, dibasic sodium phosphate dihydrate, sodium chloride, hydrochloric acid, sodium hydroxide and water for injections. PHARMACOLOGY _Pharmacodynamics _ Levemir is a soluble, basal insulin analogue with a prolonged duration of effect (Figure 1). Product Information page 2 Levemir (TZD warning etc SRN) dpi1a.doc P H A R M A C O D Y N A M I C P A R A M E T E R S F O R L E V E M I R A N D N P H L e v e m i r N P H 0 . 2 U / k g 0 . 3 U / k g 0 . 4 U / k g 0 . 3 I U / k g D u r a t i o n o f a c t i o n ( h r ) 1 2 1 7 † 2 0 1 3 G I Perskaitykite visą dokumentą